These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10690840)

  • 21. Dose to fingertips of staff preparing stranded iodine-125 seeds for permanent prostate implants.
    van Haaren PM; van't Riet A; Moerland MA; Koedooder C; Westendorp H
    Radiat Prot Dosimetry; 2011 Apr; 145(1):61-5. PubMed ID: 21112885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advanced Collapsed cone Engine dose calculations in tissue media for COMS eye plaques loaded with I-125 seeds.
    Morrison H; Menon G; Larocque MP; van Veelen B; Niatsetski Y; Weis E; Sloboda RS
    Med Phys; 2018 Jul; 45(7):3349-3360. PubMed ID: 29729009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 106Ru/106Rh plaque and proton radiotherapy for ocular melanoma: a comparative dosimetric study.
    Mourtada F; Koch N; Newhauser W
    Radiat Prot Dosimetry; 2005; 116(1-4 Pt 2):454-60. PubMed ID: 16604677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dosimetric calculations and measurements of gold plaque ophthalmic irradiators using iridium-192 and iodine-125 seeds.
    Luxton G; Astrahan MA; Liggett PE; Neblett DL; Cohen DM; Petrovich Z
    Int J Radiat Oncol Biol Phys; 1988 Jul; 15(1):167-76. PubMed ID: 3391814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On the actual state of industrial quality assurance procedures with regard to (106)Ru ophthalmic plaques.
    Kaulich TW; Zurheide J; Haug T; Budach W; Nüsslin F; Bamberg M
    Strahlenther Onkol; 2004 Jun; 180(6):358-64. PubMed ID: 15175870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
    Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
    Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. I-125 ROPES eye plaque dosimetry: validation of a commercial 3D ophthalmic brachytherapy treatment planning system and independent dose calculation software with GafChromic® EBT3 films.
    Poder J; Corde S
    Med Phys; 2013 Dec; 40(12):121709. PubMed ID: 24320495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
    Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
    Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dosimetric verification of a dedicated 3D treatment planning system for episcleral plaque therapy.
    Knutsen S; Hafslund R; Monge OR; Valen H; Muren LP; Rekstad BL; Krohn J; Dahl O
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1159-66. PubMed ID: 11704341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Individualized dosimetry in Ru-106 ophthalmic brachytherapy based on MRI-derived ocular anatomical parameters.
    Liakopoulos DA; Perisinakis K; Solomou G; Kouvidakis A; Drakonaki EE; Bontzos G; Papadaki E; Detorakis ET
    Brachytherapy; 2022; 21(6):904-911. PubMed ID: 35995724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comprehensive dosimetric comparison between (131)Cs and (125)I brachytherapy sources for COMS eye plaque implant.
    Zhang H; Martin D; Chiu-Tsao ST; Meigooni A; Thomadsen BR
    Brachytherapy; 2010; 9(4):362-72. PubMed ID: 20116342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom.
    Lesperance M; Martinov M; Thomson RM
    Med Phys; 2014 Mar; 41(3):031706. PubMed ID: 24593710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Palladium-103 versus iodine-125 for ophthalmic plaque radiotherapy.
    Finger PT; Lu D; Buffa A; DeBlasio DS; Bosworth JL
    Int J Radiat Oncol Biol Phys; 1993 Nov; 27(4):849-54. PubMed ID: 8244814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Optimizing target volume assessment in irradiation of intraocular melanomas with ruthenium applicators].
    Poier E; Langmann G; Leitner H; Vidic B
    Fortschr Ophthalmol; 1991; 88(2):158-60. PubMed ID: 1855736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dosimetric validation of the Theragenics AgX-100® I-125 seed for ROPES eye plaque brachytherapy.
    Pagulayan C; Heng SM; Corde S
    Australas Phys Eng Sci Med; 2019 Jun; 42(2):599-609. PubMed ID: 31087233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques.
    Johnson JE; Deufel CL; Furutani KM
    Brachytherapy; 2016; 15(5):661-8. PubMed ID: 27475484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapy relevant weak sites in industrial quality assurance of 106Ru eye plaques].
    Kaulich TW; Zurheide J; Flühs D; Haug T; Nüsslin F; Bamberg M
    Strahlenther Onkol; 2001 Nov; 177(11):616-23; discussion 624-7. PubMed ID: 11757185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conservative treatment of retinoblastoma. The use of plaque brachytherapy.
    Hernandez JC; Brady LW; Shields CL; Shields JA; DePotter P
    Am J Clin Oncol; 1993 Oct; 16(5):397-401. PubMed ID: 8213621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monte Carlo and thermoluminescence dosimetry of the new IsoSeed model I25.S17 125I interstitial brachytherapy seed.
    Lymperopoulou G; Papagiannis P; Sakelliou L; Karaiskos P; Sandilos P; Przykutta A; Baltas D
    Med Phys; 2005 Nov; 32(11):3313-7. PubMed ID: 16370418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosimetry for 125I seed (model 6711) in eye plaques.
    Chiu-Tsao ST; Anderson LL; O'Brien K; Stabile L; Liu JC
    Med Phys; 1993; 20(2 Pt 1):383-9. PubMed ID: 8497229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.